Take 5-Bridging the Information Gap: An HPV Education Project

Article

Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States, with approximately 20 million people currently infected and an additional 6.2 million infected each year, despite increased media attention to HPV as a cause of cervical cancer and the availability of a vaccination to reduce HPV-associated cervical cancer.

provides quick, reader-friendly snapshots of interesting people, news, and current research related to cancer and its management. These 5-point profiles take only about 5 minutes to read and often feature audio or video.

Oncology Nursing Society 36th Annual Congress

Poster/ abstract 1052135-Bridging the Information Gap: An HPV Education Project

Dionne Walker, BSN, RN; Linda Bracks-Madison, MSN, RN; Judith Payne, PhD, RN, AOCN

At the time that the HPV education project was developed, Ms. Walker was Clinical Care Coordinator for the Cord Blood Bank Program, Ms. Bracks-Madison was (and still is) working in the Division of Internal Medicine, and Dr. Payne was Associate Director of Nursing Research at The University of Texas M.D. Anderson Cancer Center, Houston, TX. Dr. Payne is currently Associate Director, Nursing Research, Duke University School of Nursing, Durham, NC.

Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States, with approximately 20 million people currently infected and an additional 6.2 million infected each year, despite increased media attention to HPV as a cause of cervical cancer and the availability of a vaccination to reduce HPV-associated cervical cancer.

Nurses are in a key position to participate in a community-based education project that will help sexually active women at risk for HPV to reduce their lifestyle risk factors for HPV, make informed health decisions regarding screening and, if needed, receive treatment for HPV infection.

The investigators evaluated the medical literature, searching the databases EBSCOHost and CINAHL Plus, using the following key words: “human papillomavirus (HPV),” “HPV-cancer,” “HPV-counseling,” “HPV-education,” and womens’ knowledge HPV,” retrieving 40 articles.

• They uncovered a lack of simple, easy-to-understand information about HPV that healthcare providers can use to inform patients about risks and how to protect themselves, and management of cervical infections with HPV.

• Based on their findings, a nurse-led community-based education project will be developed in community centers, with educational training across nursing specialties, to teach women about HPV risk factors, genotype testing, and recommended screening and treatment modalities. Information about the psychosocial aspects of HPV infection (eg, the stigma associated with sexually transmitted disease, particularly among older women, and the finding that older physicians may be inconsistent in communicating to patients about HPV risk) will inform the healthcare provider approach to patient communication.

• Efficacy of the community-based project in increasing public awareness about HPV-related cervical cancers will be assessed via surveys conducted before and after the educational intervention.

An ideal time for nurses to initiate individual patient assessments and provide education about the risk of HPV transmission and ways that women can prevent HPV infection is during wellness visits/checkups, though patient education for this project will occur at other times also.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Related Content